Hypogonadotropic hypogonadism as a cause of NOA and its treatment.
- Author:
Gianmaria SALVIO
1
;
Giancarlo BALERCIA
1
;
Ates KADIOGLU
2
Author Information
- Publication Type:Review
- Keywords: Kallmann syndrome; gonadotropins; hypogonadotropic hypogonadism; idiopathic hypogonadism
- MeSH: Humans; Hypogonadism/drug therapy*; Male; Azoospermia/drug therapy*; Gonadotropin-Releasing Hormone/therapeutic use*; Kallmann Syndrome/drug therapy*; Hormone Replacement Therapy
- From: Asian Journal of Andrology 2025;27(3):322-329
- CountryChina
- Language:English
- Abstract: Hypogonadotropic hypogonadism (HH) represents a relatively rare cause of nonobstructive azoospermia (NOA), but its knowledge is crucial for the clinical andrologists, as it represents a condition that can be corrected with medical therapy in 3 quarters of cases. There are forms of congenital HH, whether or not associated with an absent sense of smell (anosmic HH or Kallmann syndrome, and normosmic HH, respectively), and forms of acquired HH. In congenital HH, complete absence of pubertal development is characteristic. On the other hand, if the deficit occurs after the time of pubertal development, as in acquired HH patients, infertility and typical symptoms of late-onset hypogonadism are the main reasons for seeking medical assistance. Gonadotropin-releasing hormone (GnRH) or gonadotropin replacement therapy is the mainstay of drug therapy and offers excellent results, although a small but significant proportion of patients do not achieve sufficient responses.
